You are here

About us>Scientific Advisory Board

Dr. Fraser Murray, PhD, MBA

Fraser has over 20 years experience in the pharmaceutical industry, ranging from small start up biotech to large multinational pharmaceutical companies. Fraser began his career with Merck & Co. at their Neuroscience Research Centre in the UK working on a range of neurodegeneration and psychiatry projects. He then moved to AstraZeneca's Respiratory and Inflammation research group where he worked on osteoarthritis, rheumatoid arthritis and pain. In 2011 he took a role with Shire where he was a Senior Director and had responsibility for Discovery Biology for Shire's CNS and GI discovery portfolio. In addition to his role with Arisgen, Fraser is also Vice President of Biology at Calcico Therapeutics, a venture backed spin out from the University of Oxford. Fraser is also a Co-founder and Director of Polleo Pharma, a spin out company from Shire looking to develop leading therapies for behavioural health disorders. Fraser obtained his BSc in Immunology and Pharmacology from the University of Strathclyde, his PhD in Neuropharmacology from the School of Pharmacy, University of London and his MBA from Manchester Business School, University of Manchester.

Frédéric Preitner holds a Ph.D. in Medical Biochemistry (University of Geneva) in the field of obesity. He then performed a post-doctoral training in the field of insulin secretion at University of Lausanne, and a second post-doctoral training in the field of Insulin action at BIDMC/Harvard Medical School, Boston. Since September 2006 he is developping and running the Mouse metabolic Facility at University of Lausanne. His team has performed in vivo validation of Ariscrown formulations since August 2007. www.unil.ch/mef/

Graduated in Medicine cum laude (1980) at University of “G. D’Annunzio” School of Medicine, Chieti, Italy.Postdoctoral fellow of the Italian National Research Council (CNR), Roma, Italy and Assistant Professor at the Institute of Biochemical Sciences, Università "G. D'Annunzio", Chieti, Italy.Since 1984, Dr. Arduini has spent several years in various prestigious academic centers in the U.S.Dr. Arduini has several years of industry experience as head of the department of Metabolic Diseases in Sigma Tau Pharmacetical Industries, Pomezia, Italy, as disease area head of the department of Metabolic Diseases in Hoffman-La Roche, Basel, Switzerland, and as head of the department of Metabolic Diseases in DARA BioSciences, Raleigh, NC, USA. Dr. Arduini also founded several research driven pharmaceutical companies in Italy and Switzerland. These experiences have given him a unique perspective on the issues involved in drug discovery and development. During his academic and industrial carrier, Dr. Arduini has established scientific background and experimental tools leading to the discovery of novel pathways in different fields such as oxidative stress, ischemia-reperfusion injury (cardiovascular), lipid metabolism, diabetes and obesity. He has discovered and developed new chemical entities in the metabolic and cardiovascular fields, and new crystalloid solutions in the peritoneal dialysis and transfusion medicine fields.Dr. Arduini’s research has resulted in more than 90 peer reviewed papers, 30 international patents, and 15 book chapters and reviews. He serves as a reviewer for several scientific journals.